within Pharmacolibrary.Drugs.ATC.N;

model N02AF01_1
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 0.00015666666666666666,
    adminDuration  = 600,
    adminMass      = 2 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.28,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.23,
    k12             = 52.5,
    k21             = 52.5
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>N02AF01_1</td></tr><td>route:</td><td>intranasal</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Butorphanol is a synthetic opioid analgesic used for the management of moderate to severe pain, including pain associated with surgery, migraine, and cancer. It acts primarily as an agonist-antagonist at opioid receptors (agonist at kappa and partial agonist/antagonist at mu receptors). Butorphanol is approved and currently used in both human and veterinary medicine, with formulations available for intravenous, intramuscular, and nasal administration.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adults following intranasal administration.</p><h4>References</h4><ol><li><p>Sha, J, et al., &amp; Ponnampalam, J (2022). Pharmacokinetics and Pharmacodynamics of Butorphanol and Dexmedetomidine after Intranasal Administration in Broiler Chickens (. <i>Veterinary sciences</i> 9(5) –. DOI:<a href=\"https://doi.org/10.3390/vetsci9050212\">10.3390/vetsci9050212</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/35622740/\">https://pubmed.ncbi.nlm.nih.gov/35622740</a></p></li><li><p>Davis, GA, et al., &amp; Wermeling, DP (2004). Pharmacokinetics of butorphanol tartrate administered from single-dose intranasal sprayer. <i>American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists</i> 61(3) 261–266. DOI:<a href=\"https://doi.org/10.1093/ajhp/61.3.261\">10.1093/ajhp/61.3.261</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/14986556/\">https://pubmed.ncbi.nlm.nih.gov/14986556</a></p></li><li><p>Okur, S, et al., &amp; Gumurcinler, B (2023). Sedative and cardiopulmonary effects of intranasal butorphanol with midazolam or dexmedetomidine in New Zealand white rabbits. <i>The Veterinary record</i> 193(1) e2999–None. DOI:<a href=\"https://doi.org/10.1002/vetr.2999\">10.1002/vetr.2999</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/37183183/\">https://pubmed.ncbi.nlm.nih.gov/37183183</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end N02AF01_1;
